全文获取类型
收费全文 | 10327篇 |
免费 | 840篇 |
国内免费 | 16篇 |
专业分类
耳鼻咽喉 | 149篇 |
儿科学 | 229篇 |
妇产科学 | 180篇 |
基础医学 | 1304篇 |
口腔科学 | 211篇 |
临床医学 | 928篇 |
内科学 | 2113篇 |
皮肤病学 | 96篇 |
神经病学 | 993篇 |
特种医学 | 294篇 |
外科学 | 1634篇 |
综合类 | 329篇 |
一般理论 | 8篇 |
预防医学 | 1053篇 |
眼科学 | 215篇 |
药学 | 876篇 |
1篇 | |
中国医学 | 9篇 |
肿瘤学 | 561篇 |
出版年
2022年 | 56篇 |
2021年 | 150篇 |
2020年 | 96篇 |
2019年 | 147篇 |
2018年 | 202篇 |
2017年 | 149篇 |
2016年 | 144篇 |
2015年 | 180篇 |
2014年 | 282篇 |
2013年 | 448篇 |
2012年 | 655篇 |
2011年 | 668篇 |
2010年 | 390篇 |
2009年 | 397篇 |
2008年 | 768篇 |
2007年 | 813篇 |
2006年 | 788篇 |
2005年 | 744篇 |
2004年 | 776篇 |
2003年 | 661篇 |
2002年 | 669篇 |
2001年 | 114篇 |
2000年 | 52篇 |
1999年 | 106篇 |
1998年 | 124篇 |
1997年 | 130篇 |
1996年 | 107篇 |
1995年 | 96篇 |
1994年 | 87篇 |
1993年 | 65篇 |
1992年 | 55篇 |
1991年 | 54篇 |
1990年 | 40篇 |
1989年 | 50篇 |
1988年 | 49篇 |
1987年 | 31篇 |
1986年 | 53篇 |
1985年 | 51篇 |
1984年 | 57篇 |
1983年 | 66篇 |
1982年 | 83篇 |
1981年 | 76篇 |
1980年 | 62篇 |
1979年 | 35篇 |
1978年 | 46篇 |
1977年 | 31篇 |
1976年 | 46篇 |
1975年 | 29篇 |
1974年 | 24篇 |
1973年 | 32篇 |
排序方式: 共有10000条查询结果,搜索用时 468 毫秒
11.
12.
13.
A number of neurotransmitters and neuropeptides in the hypothalamus play a role in the control of food intake, metabolism, and body weight. Particularly, noradrenergic mechanisms in several areas of the hypothalamus are involved. Control of peripheral metabolism by the hypothalamus is achieved via autonomic modulation of the function of hepatocytes, adipocytes, and the endocrine cells in the islets of Langerhans. The autonomic control mechanisms ultimately lead to an appropriate shaping of blood glucose, plasma FFA, and insulin profiles to guarantee an adequate flow of nutrients under different physiological situations. Peripheral insulin and glucose can penetrate into the brain where they might affect the function of those brain structures involved in control of food intake, metabolism, and body weight. 相似文献
14.
Kelly Garrett Allison Butler Wayne R Cohen 《The journal of maternal-fetal & neonatal medicine》2005,17(1):49-53
OBJECTIVE: To characterize dysfunctional labors that lead to cesarean delivery in the second stage and to assess the accuracy of diagnoses of abnormal fetal descent. METHODS: Thirty-one patients delivered by cesarean during the second stage because of abnormal labor or presumed cephalopelvic disproportion were studied and compared to 62 control cesarean cases delivered for the same indications in the first stage. The clinical diagnosis of dysfunctional labor that led to the cesarean was compared to the diagnosis made by retrospective analysis of the labor curves. RESULTS: Cases did not differ from controls delivered in the first stage in maternal age, race, parity, gestational age, weight gain, or the frequency of associated medical complications. The newborns were not significantly different in birth weight,ponderal index, sex, or the incidence of low Apgar scores. Among study patients, 94% had a second stage labor dysfunction determined by graphic labor analysis, predominantly arrest of descent (69%) and failure of descent (28%). In 79% of cases a dysfunctional first stage preceded the abnormal second stage. Among these first stage labor abnormalities, 68% were not recognized during the labor. CONCLUSION: Characteristics of patients delivered by cesarean during the second stage were similar to those delivered before full cervical dilatation. Second stage labor abnormalities were usually preceded by an abnormal first stage. There was considerable inaccuracy in the diagnosis of second stage labor dysfunction. 相似文献
15.
Najat C Daw Wayne L Furman Clinton F Stewart Lisa C Iacono Mark Krailo Mark L Bernstein Janet E Dancey Rose Anne Speights Susan M Blaney James M Croop Gregory H Reaman Peter C Adamson 《Journal of clinical oncology》2005,23(25):6172-6180
PURPOSE: Epidermal growth factor receptor is expressed in pediatric malignant solid tumors. We conducted a phase I trial of gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, in children with refractory solid tumors. PATIENTS AND METHODS: Gefitinib (150, 300, 400, or 500 mg/m2) was administered orally to cohorts of three to six patients once daily continuously until disease progression or significant toxicity. Pharmacokinetic studies were performed during course one (day 1 through 28). RESULTS: Of the 25 enrolled patients, 19 (median age, 15 years) were fully evaluable for toxicity and received 54 courses. Dose-limiting toxicity was rash in two patients treated with 500 mg/m2 and elevated ALT and AST in one patient treated with 400 mg/m2. The maximum-tolerated dose was 400 mg/m2/d. The most frequent non-dose-limiting toxicities were grade 1 or 2 dry skin, anemia, diarrhea, nausea, and vomiting. One patient with Ewing's sarcoma had a partial response. Disease stabilized for 8 to > or = 60 weeks in two patients with Wilms' tumor and two with brainstem glioma (one exophytic). At 400 mg/m2, the median peak gefitinib plasma concentration was 2.2 microg/mL (range, 1.2 to 3.6 microg/mL) and occurred at a median of 2.3 hours (range, 2.0 to 8.3 hours) after drug administration. The median apparent clearance and median half-life were 14.8 L/h/m2 (range, 3.8 to 24.8 L/h/m2) and 11.7 hours (range, 5.6 to 22.8 hours), respectively. Gefitinib systemic exposures were comparable with those associated with antitumor activity in adults. CONCLUSION: Oral gefitinib is well tolerated in children. Development of the drug in combination with cytotoxic chemotherapy will be pursued. 相似文献
16.
17.
18.
19.
20.
Betlach Charles J. Arnold John D. Frost R. Wayne Leese Philip T. Gonzalez Mario A. 《Pharmaceutical research》1987,4(5):409-411
The bioavailability of a new sustained-release potassium chloride (KC1) tablet, designed for once-a-day dosing, was compared to a KC1 elixir using urinary excretion data. The study utilized 25 male volunteers dosed in a crossover design in a dietary/activity-controlled environment. The regimens consisted of a total of 80 mEq of potassium in three equally divided doses of elixir every 6 hr and a single 80-mEq dose using four 20-mEq sustained-release (SR) tablets. The mean time to maximum rate of potassium urinary excretion was 2.2 hr for the first elixir dose and 5.5 hr after the SR tablet (P < 0.01), thereby supporting the prolonged-release properties of this formulation. After correction for baseline urinary potassium excretion, the mean total 24-hr urinary potassium excretion was 42.18 mEq for the elixir and 40.41 mEq for the SR tablet. The results indicate that the absorption pattern from the SR tablet is equal to three doses of KC1 elixir dosed 6 hr apart. 相似文献